Abstract: This invention relates to oral care compositions comprising a first source of zinc which is zinc citrate, a second source of zinc which is zinc oxide or zinc lactate, a stannous ion source, and a polyphosphate, as well as to methods of using and of making these compositions.

Abstract: An oral care composition comprising zinc phosphate, stannous fluoride and an organic acid buffer system, as well as methods of using the same.

Abstract: The present invention relates to a cosmetic and/or dermatological composition comprising, in a physiologically acceptable medium: a) one or more alcohols comprising at least 20 carbon atoms, b) one or more fatty acid esters, said ester comprising at least 24 carbon atoms, and being selected among A) those corresponding to the formula (I) below: R—COO—R???(I) in which: R and R?, which may be identical or different, denote a saturated or unsaturated, linear or branched, hydrogenated or non-hydrogenated hydrocarbon-based group comprising from 12 to 30 carbon atoms and preferably from 14 to 24 carbon atoms, and B) di- or triesters of glycerol and of C12-C30 fatty acids; and c) at least one or more thickeners which are not xanthan gum. Another subject of the invention is a process for mattifying the skin and/or reducing the shininess thereof. Another subject of the invention is the use of said fatty acid ester as agent for mattifying keratin materials such as the skin.

Abstract: The present invention relates to a method for producing a liquid composition for oral cavity in which ?-glycyrrhetinic acid is stably dispersed or dissolved to exhibit an increased transparency and which also can ensure a sufficient amount of ?-glycyrrhetinic acid adsorbed on gingiva, even if the amount of a cationic surfactant or an anionic surfactant is restricted; and such a liquid composition for oral cavity. Specifically, the present invention relates to a method for producing a liquid composition for oral cavity, comprising the following step 1 to step 4: (Step 1) a step of blending water (F) with an organic acid and a salt thereof (E) to adjust the pH of a resultant mixture to 5 or more and 6.8 or less, (Step 2) a step of blending 0.02% by mass or more and 0.1% by mass or less of cetylpyridinium chloride (B) into the mixture, (Step 3) a step of blending 0.02% by mass or more and 0.

Abstract: The present invention relates to the cosmetic use, in a composition containing a physiologically acceptable medium, of at least one compound of formula (I) in which: —R3 means a hydrogen atom or a hydroxyl radical, —R1 and R2 mean, independently of each other, a hydrogen atom, a linear or branched C1-C6 alkyl radical; a benzyl radical; a linear or branched C1-C6 alkylcarbonyl radical not conjugated with the carbonyl; or a linear or branched C1-C6 alkoxycarbonyl radical, and/or of an isomer and/or of a salt and/or of a solvate of said compound of formula (1), for preventing and/or treating the signs of ageing of the skin and its appendages.

Abstract: This invention relates to oral care compositions comprising zingerone, a stannous ion source, zinc oxide, and zinc citrate, as well as to methods of using and of making these compositions.

Abstract: Provided herein are a cosmetic composition, a health functional food composition, a pharmaceutical composition, and a quasi-drug composition that include ionone or a salt thereof as an active ingredient and have an effect of enhancing skin moisturizing, exfoliating skin, improving skin elasticity, inhibiting erythema, improving skin wrinkles, or alleviating skin photoaging.

Abstract: A shampoo composition and a method of making a shampoo composition which delivers both good conditioning benefits and good lather performance. The shampoo composition comprises a dispersed gel network phase comprising: from about 2.8 weight % to about 8 wt % of one or more fatty alcohols; at least 0.01% of one or more secondary surfactants, wherein the secondary surfactant comprises sodium laureth-n sulfate wherein n is from about 0 to about 5; and water; and from about 5% to about 50% of a detersive surfactant; from about 0.02% to about 1.50% of a material selected from the group consisting of structurants, suspending agents and mixtures thereof, from about 0.5 to about 1% of a cationic deposition polymer; and at least 20% of an aqueous carrier.

Abstract: Provided herein is an oral care composition comprising taurine or a salt thereof in an amount of from 0.001 weight % to 0.008 weight % by total weight of the composition, and an orally acceptable carrier. The composition is effective in accelerating HSP 27 production in damaged tissues of the oral cavity and enhances repair of the damaged tissue.

Abstract: A cosmetic composition suitable for topical application is provided. The cosmetic composition comprises: glycerin; a lipid bilayer structurant with a glyceryl headgroup; a penetration enhancer; and a skin care active. The penetration enhancer increases the amount of active that enters skin when the composition is topically applied, while the glycerin and lipid bilayer structurant with glyceryl headgroup work together with lipid bilayers of the skin to impede progress of active through the skin.

Abstract: Hair improvement compositions comprising covalent conjugates of a polypeptide and a hydrophilic polymer, or a polysaccharide and a hydrophilic polymer, or both, are provided herein. Methods for improving one or more physical characteristics of hair using the described compositions are also provided. The improvements can be semi-permanent.

Abstract: The present invention relates, e.g., to a system for treating damaged skin, comprising a cosmeceutical formulation comprising about 1-10% of a mixture of perfluorocarbons (PFC's) of at least three different molecular weights, and about 0.001-5% hyaluronic acid (HA) of molecular weight about 100 kDa or less, packaged in an aerosol spray container.

Abstract: A water-based cosmetic including: agar having a weight average molecular weight of 10,000 to 60,000 (component (A)); xanthan gum (component (B)); and a water-soluble polymer excluding the component (A) or (B) (component (C)).

Abstract: Cosmetic emulsions are disclosed that can remain stable even with relatively high salt based cosmetic astringent content. In one aspect, an emulsion can include a water phase including water and a rheology modifier including Microcrystalline Cellulose and Cellulose Gum. The emulsion can also include an oil phase comprising Steareth-2 and Glyceryl Stearate and an emulsifier selected from the group consisting of: Steareth-20, Steareth-21, and combinations thereof. The emulsion can include a salt based cosmetic astringent providing at least about 1.0% of the emulsion by weight.

Abstract: A rinse off hair treatment composition comprising; a. a pressure sensitive adhesive emulsion comprising one or more pressure sensitive polymer, wherein the pressure sensitive polymer is not silicone pressure sensitive polymer, and b. at least one material selected from the group consisting of i) a hair conditioning agent; ii) a hair cleansing agent, and, c. a deposition aid.

Abstract: A hair care composition comprising: i) at least one crosslinked nonionic amphiphilic suspending polymer; ii) at least one anionic surfactant; iii) at least one particulate antidandruff agent; and iv) water. The suspending polymer is a pH independent nonionic, amphiphilic emulsion polymer that is crosslinked with an amphiphilic crosslinking agent and effectively suspends water insoluble particulate antidandruff agents.

Abstract: Provided is a polylactic-acid-containing aqueous dispersion capable of forming a transparent film at room temperature. A polylactic-acid-containing aqueous dispersion contains (1) polylactic acid; (2) at least one plasticizer selected from the group consisting of dimethyl adipate, diethyl adipate, dipropyl adipate, diisopropyl adipate, dibutyl adipate, diallyl adipate, bis(2-butoxyethyl) adipate, bis(2-methoxyethyl) adipate, dimethyl succinate, dimethyl glutarate, diethyl sebacate, diisopropyl sebacate, and mixtures thereof; (3) at least one dispersion stabilizer selected from the group consisting of cationic polymers, anionic polymers, polyvinyl alcohols, and non-ionic surfactants; and (4) water.

Abstract: The present invention relates to the cosmetic use as a skin refreshing agent of the combination of at least one associative nonionic polyether polyurethane and at least one cyclohexanol derivative. The present invention also relates to a cosmetic method for refreshing the skin, consisting in applying to the skin surface a composition comprising, in particular in a cosmetically acceptable medium: a) an aqueous phase; and b) at least one associative nonionic polyether polyurethane; and c) at least one cyclohexanol derivative. The present invention also relates to a composition comprising, particularly in a physiologically acceptable medium: a) at least one aqueous phase; and b) at least one associative nonionic polyether polyurethane; and c) at least one cyclohexanol derivative; and d) at least one antiperspirant active agent.

Abstract: The invention relates to a dispersion of polymer particles stabilized with a stabilizer in a nonaqueous medium containing at least one hydrocarbon-based oil, the polymer of the particles being a C1-C4 alkyl (meth)acrylate polymer; the stabilizer being a C1-C4 alkyl (meth)acrylate polymer and optionally of a silicone macromonomer (I): the stabilizer being a polymer comprising from 50% to 100% by weight, relative to the total weight of the stabilizer, of C8-C22 alkyl acrylate, from 0 to 50% by weight of C1-C4 alkyl (meth)acrylate and optionally silicone macromonomer (I). The invention also relates to the composition comprising said dispersion of polymer particles. Cosmetic use for caring for and making up keratin materials.

Abstract: An alkalizing delivery system for promoting healthier saliva is provided. The alkalizing delivery system may take many portable forms that include a saliva buffering agent and a saliva alkali agent adapted to transiently change the pH balance of a user's saliva without the use of self-foaming agents.

Abstract: Compositions are provided that include date palm pollen or an extract thereof. The compositions may be formulated for topical use in methods of treatment or prophylaxis of various skin conditions or methods to counteract the effects of skin aging.

Abstract: The present invention provides a pharmaceutical composition for delivering palonosetron through the buccal mucosa or sublingual mucosa. The pharmaceutical composition comprises 0.05-35% (w/w) of palonosetron, 40-90% of a film forming agent, 1-10% (w/w) of a plasticizer, 5-25% (w/v) of an adhesive agent, and 0.1-5% of a penetration enhancing agent. A preferred plasticizer is a polysorbate. A preferred adhesive agent is polyvinylpyrrolidone or carboxymethylcellulose. A preferred penetration enhancing agent is peppermint oil or menthol.

Abstract: The invention provides allergen containing pharmaceutical products and in particular fast-dispersing solid allergen dosage forms. In particular, fast-dispersing, non-compressed solid dosage forms suitable for oromucosal administration comprising a matrix and at least one allergen are provided. Suitable matrices are gelatine, starch and mannitol. Methods for the dosage forms are also provided.

Abstract: The present invention relates to a novel propellant-gas-containing medicament composition based on tiotropium 1, processes for the preparation thereof and the use of such medicament compositions in the treatment of respiratory complaints.

Abstract: The present invention relates to methods and compositions for the treatment of infections of the nails, in particular the treatment of onychomycosis.

Abstract: A composition comprising lipid and surfactant, characterised in that the surfactant has an HLB number of less than 20 and in that the lipid and surfactant are in the form of macromolecular assemblies of less than 10 nm in diameter.

Abstract: Implantable devices including a biocompatible matrix configured for long term location in adipose tissue and a biologically active agent that can be carried by the matrix and delivered to the adipose tissue following implant therein. The biologically active agent can include a modulator or a precursor thereof that can directly or indirectly modify the gene expression of adipose cells, e.g., adipocytes, and thereby modify the presence or quantity of one or more expression products of the adipose tissue that may act locally on distant from the implant site in an endocrine fashion. Modulators can include small molecules (e.g., resveratrol), polynucleotides (e.g., RNAi), or polypeptides (e.g., antibodies or functional fragments thereof).

Abstract: A pharmaceutical tablet for use in administering one or more pharmaceutically active ingredients, comprising a polymer system, the one or more pharmaceutically active ingredients, a flavor, and a sweetener, wherein at least 20% by weight of the pharmaceutical tablet comprises substantially non-elastomeric polymer and less than 5% by weight of the pharmaceutical tablet comprises one or a combination of elastomeric polymers, and wherein the pharmaceutical tablet comprises at least 70% by weight of said polymer system comprising polyvinyl acetate (PVA) and less than 10% by weight of said polymer system comprising polymer having a molecular weight (Mw) greater than 50,000 g/mol.

Abstract: Provided according to embodiments of the invention pharmaceutical capsules that include a capsule body and a capsule cap, wherein the capsule cap envelops an open end of the capsule body to form a capsule core; and an adherence sheath that envelops a portion of the capsule core. Related capsules and methods of making such capsules are also provided herein.

Abstract: A technique is provided for reducing the discoloration of an aqueous composition containing a halogenated isoquinoline derivative during high-temperature preservation. An aqueous composition comprising a compound represented by Formula (1): wherein X represents a halogen atom, or a salt thereof, or a solvate of the compound or the salt thereof, and a ? blocker.

Abstract: This invention provides a topical drug formulation and methods for the preparation thereof. This invention further provides the use of said drug formulation in pharmaceutical compositions and methods of treating mammals. This invention also provides the use of said drug formulation in pharmaceutical compositions for dermatological and transdermal applications. More specifically, this invention provides an aqueous-based drug formulation which has increased storage stability and controlled drug release upon application. The present application also describes materials and methods useful in creating such drug formulations.

Abstract: The present invention provides methods of treating arthritis. A sustained release composition comprising liposomes and one or more therapeutic agent or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof. The liposomes may be in an aqueous suspension. The sustained release composition can be administered intraarticularly.

Abstract: Nano-sized particles are provided comprising at least one multi-headed amphiphilic compound, in which at least one headgroup of said multi-headed amphiphilic compound is selectively cleavable or contains a selectively cleavable group, and at least one biologically active agent, which is both encapsulated within the nano-particle and non-covalently associated thereto.

Abstract: A method for treating an ocular disorder in a subject comprising administering a therapeutic agent-loaded carrier to an ocular site of the subject in need thereof, wherein the therapeutic agent loaded-carrier provides controlled delivery of the therapeutic agent under conditions suitable for recruiting regulatory T cells to an ocular region of interest or inducing regulatory T cells in an ocular region of interest.

Abstract: Provided herein are compositions and methods for diagnosis and treatment of early-stage atherosclerotic plaques and reduction of plaques in arteries. In particular, provided herein are high-density-lipoprotein-functionalized magnetic nanostructures (HDL-MNS) capable of (i) precise anatomic detection of atherosclerotic lesions, (ii) removal of excess cholesterol from macrophage cells in atherosclerotic plaque, and/or (iii) delivery of therapeutic agents to plaque locations, and methods of diagnosis and treatment of atherosclerosis.

Abstract: Described herein is a solid tablet that is directly-compressed of powder, including meloxicam and one or more excipients which are homogenously dispersed within the tablet that can be broken into two, three or four units with each unit containing equal amounts of the active ingredient, meloxicam.

Abstract: The present invention relates to an edible composition having a lipid continuous phase and self-assembled structures, the composition comprising oil, phospholipids, caffeine and water. Further aspects of the invention are the use of a composition to provide controlled release of caffeine, a composition for use in the treatment or prevention of drowsiness, the non-therapeutic use of a composition to increase mental alertness, and an edible capsule.

Abstract: A food safe, plant based, water soluble, dry powder formulation and an aqueous enteric coating solution made therefrom, that is used for providing an enteric film coating on oral dosage forms including capsules, tablets, and the like; and methods of making the dry powder formulation, making the aqueous coating solution, and coating of oral dosage forms including capsules, tablets, and the like.

Abstract: The invention provides a slow-release material comprising particles, wherein the particles comprise a core comprising an active component and a multilayer shell, wherein the multi-layer shell comprises a molecular layer deposition (MLD) multi-layer, wherein the active component comprises one or more of a pharmaceutical compound and a nutraceutical compound, for use in the treatment of a disease.

Abstract: The invention relates to compositions and methods for attenuating opioid induced respiratory depression. Such compositions comprise opioids and sequestered opioid antagonists in a multi-particulate dosage formulation.

Abstract: Disclosed herein are lipid nanoparticles comprising a lipid phase and at least one lipophilic anti-inflammatory agent, and pharmaceutical compositions comprising lipid nanoparticles and methods for using lipid nanoparticles.

Abstract: Nanoparticles include a polymeric core and a high density lipoprotein (HDL) component where the ratio by weight of the HDL component to the polymeric core is in a range from about 1:9 to about 9:1, such as about 75:25 or less or about 7:3 or less. The nanoparticles may also include a mitochondria targeting moiety. The nanoparticles may be used to treat or prevent atherosclerosis or to maintain lipid homeostasis.

Abstract: The present invention relates to methods, combinations and pharmaceutical compositions for supplying a blood source from a donor source with a mis-matched blood type, or potentially a mis-matched blood type, to a recipient, using, inter alia, an effective amount of a nanoparticle comprising a) an inner core comprising a non-cellular material, and b) an outer surface comprising a cellular membrane derived from a red blood cell, the cellular membrane of the nanoparticle comprising a blood type antigen that exists on the red blood cell from the donor source, but is missing or potentially missing on red blood cells of the recipient.

Abstract: A tissue thickness compensator may generally comprise a compressible core comprising a plurality of movable particles, and a wrap surrounding the compressible core. The plurality of movable particles may comprise at least one medicament. A tissue thickness compensator may generally comprise a compressible core comprising a plurality of crushable particles, and a wrap surrounding the compressible core. The plurality of crushable particles may comprise at least one medicament. The compressible core may comprise a material selected from a group consisting of a biocompatible material. The wrap may comprise a material selected from a group consisting of a biocompatible material. Articles of manufacture comprising the tissue thickness compensator and methods of making and using the tissue thickness compensator are also described.

Abstract: The present invention relates to a drug delivery system comprising a core and a shell in which the core comprises a hydrolytically degradable polymer X which polymer backbone comprises pendant ester and acid functionalities and in which the shell comprises a hydrolytic degradable polymer Y. The hydrolytic degradable polymers X and Y are different polymers. Polymer X further comprises amino-acids in the polymer backbone and degrades via zero order degradation kinetics for a period of at least 3 months. Polymer Y degrades via auto-acceleration degradation kinetics.

Abstract: The present invention addresses the problem of providing a film preparation that enables large quantities of medicinal products to be blended thereinto. The present invention provides a film preparation that contains a film base material, which contains a water-soluble polymer, and medicinal product containing particles, which are supported on the film base material and which have a coating layer containing a hydrophobic coating agent on the outermost surface of the particles. The content of the medicinal product in the medicinal product-containing particles may be 0.1-95 mass % relative to the overall film preparation. The water-soluble polymer may include one or more types selected from the group consisting of hydroxypropyl cellulose, hydroxypropylmethyl cellulose and pullulan.

Abstract: The present invention provides transdermal absorption preparation having a support, and a drug-containing adhesive layer formed on the support, wherein a drug-containing adhesive layer contains donepezil or a salt thereof, and a higher fatty acid salt.

Abstract: The invention provides a method for treating a subject suffering from early stage Parkinson's disease with a pharmaceutical formulation containing an olive polyphenol composition. The olive polyphenol composition includes hydroxytyrosol and at least one additional olive polyphenol, and the hydroxytyrosol represents about 40 wt. % to about 90 wt. % of the olive polyphenol composition. The formulation is administered to the subject within the context of a dosing regimen that provides a daily dosage of the olive polyphenol composition in the range of 30 mg to about 2500 mg. The invention additionally provides a method for reducing the dose of an antiparkinsonism drug used in the treatment of early stage Parkinson's disease, as well as a pharmaceutical formulation for treating early stage Parkinson's disease.

Abstract: In one embodiment, the invention provides a method of enhancing a subject's macular pigment optical density, the method comprising administering to the subject a pharmaceutically effective amount of one or more Xanthophyll carotenoids. Preferably, the Xanthophyll carotenoids are selected from the group consisting of lutein (L), zeaxanthin (Z), and meso-zeaxanthin (MZ), and enantiomers, metabolites, esters, pharmaceutically acceptable salts and derivatives thereof. In certain embodiments, the Xanthophyll carotenoids such as lutein (L), zeaxanthin (Z), and meso-zeaxanthin (MZ) are each in substantially pure enantiomeric form.

Abstract: To provide a therapeutic agent for cancer having a higher therapeutic effect. A therapeutic agent for cancer, containing: at least one selected from the group consisting of curcumin and a derivative thereof; and at least one selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, and an anti-PD-L2 antibody in combination.